Wolff Wiese Magana LLC Has $279,000 Holdings in Boston Scientific Co. (NYSE:BSX)

Wolff Wiese Magana LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 5.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,120 shares of the medical equipment provider’s stock after buying an additional 175 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Boston Scientific were worth $279,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. BOKF NA grew its stake in Boston Scientific by 14.0% during the second quarter. BOKF NA now owns 3,065 shares of the medical equipment provider’s stock worth $236,000 after buying an additional 377 shares during the last quarter. Parallel Advisors LLC grew its position in Boston Scientific by 15.3% during the 2nd quarter. Parallel Advisors LLC now owns 11,790 shares of the medical equipment provider’s stock worth $908,000 after acquiring an additional 1,562 shares during the last quarter. Thoroughbred Financial Services LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $203,000. J.W. Cole Advisors Inc. raised its position in Boston Scientific by 9.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,989 shares of the medical equipment provider’s stock valued at $307,000 after purchasing an additional 336 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in shares of Boston Scientific during the second quarter worth $484,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.7 %

Boston Scientific stock opened at $96.28 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a 50-day moving average of $90.36 and a 200-day moving average of $84.15. The company has a market cap of $141.90 billion, a price-to-earnings ratio of 79.57, a P/E/G ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a one year low of $59.61 and a one year high of $97.13.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter last year, the company posted $0.50 earnings per share. Boston Scientific’s quarterly revenue was up 19.3% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 in the last ninety days. 0.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BSX. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Citigroup upped their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Mizuho increased their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.